OVERVIEW

The 2022 Symposium will focus on recent advances in the diagnosis, classification and management of patients with myelodysplastic syndromes (MDS). The program combines evidence on current practice with information that might be applied in the future.

 TARGET AUDIENCE

This activity is designed for an audience of pharmacists, physicians, and nurses.

 LEARNING OBJECTIVES

Participants will learn about novel information obtained over the last decade and will hear about potential applications in the field of MDS.

More specifically:

• Review the history of myelodysplastic syndromes.
• Project future developments of myelodysplastic syndromes.
• Analyze current evidence of the use of ESAs in MDS and the potential alternatives as a second line treatment.
• Compare the contribution of real-world data with evidence obtained in clinical trials explaining how to address this information.
• Recognize the role that inflammation has in MDS pathogenesis and the influence of aging and comorbidities on these diseases.
• Identify the new molecular classification (IPSS-M) of MDS as well as the role of genetic testing in patient evaluation.
• Describe the influence of anemia on quality of life and other non-hematopoietic organ function.
• Discuss management of patients with MDS

ACCREDITATION

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 3.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For more information please visit the official event page.